The Roundup lawsuit is not fully settled yet. Thousands of individual cases are still working through courts in 2026, even after Bayer paid out more than $10 billion to resolve a large wave of claims starting in 2020.
If you used Roundup and were later diagnosed with non-Hodgkin’s lymphoma, you may still have a valid claim. This article covers exactly where things stand right now.
You’ll learn about payout amounts, who qualifies, filing deadlines, and what the legal fights in 2026 actually mean for people waiting on answers.
One fact that surprises most people: Bayer has never admitted Roundup causes cancer. Despite paying billions, the company still defends its product in court.
When Will the Roundup Lawsuit Be Settled?
There is no single end date for the Roundup lawsuit, and a complete global resolution in 2026 is unlikely.
Bayer resolved roughly 125,000 claims through its 2020 settlement agreement, paying approximately $10.9 billion. That covered a massive portion of existing cases. But it did not end the litigation entirely.
New claims continue to be filed. Some plaintiffs who were not part of that original wave are still in litigation. And Bayer faces ongoing state court trials while simultaneously pushing for broader legal protections at the federal level.
The realistic picture for 2026 is this: most legacy cases are wrapped up or in final payout stages. New and unresolved cases will take longer, potentially stretching into 2027 and beyond for some plaintiffs.
| Status Category | Current Situation (2026) |
|---|---|
| Original 2020 settlement wave | Largely resolved, payments ongoing |
| New post-2020 claims | Active litigation, no global deal yet |
| Federal MDL 2741 | Ongoing case management |
| State court trials | Individual trials continuing |
| Supreme Court preemption issue | Still a factor in case outcomes |
Key point: If you are waiting on a payout from the original settlement, your case may be in the claims processing queue. If you have not yet filed, you are dealing with a different timeline entirely.
Roundup Lawsuit Update 2026
The biggest development in 2026 is Bayer’s continued push for federal preemption protection.
Bayer argues that because the EPA approved Roundup’s label and concluded glyphosate is not likely to be carcinogenic, state courts should not be allowed to hold the company liable for failing to add cancer warnings. That argument, if accepted by the U.S. Supreme Court, would effectively end most future Roundup lawsuits.
The Supreme Court has not issued a final ruling on this preemption question as of early 2026. Lower federal courts have split on the issue, which is exactly the kind of circuit conflict that gets the Supreme Court’s attention.
For claimants in 2026, this creates real uncertainty. A ruling in Bayer’s favor could cut off thousands of pending and future claims overnight.
On the other side, plaintiffs’ attorneys are pushing forward with individual state court trials, continuing to win verdicts in some jurisdictions. Those wins create pressure on Bayer to keep settling rather than risk more jury awards.
The 2026 dynamic is essentially a waiting game between two outcomes: a Supreme Court ruling that shuts down future claims, or continued pressure from trial verdicts that forces more settlements.
Bayer Roundup Lawsuit Status 2026
Bayer AG, which acquired Monsanto in 2018 for $63 billion, inherited the entire Roundup litigation along with that purchase.
As of 2026, the company has:
- Paid approximately $10.9 billion to resolve the bulk of existing Roundup claims
- Set aside additional reserves for ongoing and future litigation
- Filed petitions seeking Supreme Court review of the preemption issue
- Continued to defend individual cases at trial in state courts
Bayer maintains that glyphosate, the active ingredient in Roundup, is safe when used as directed. The company points to the EPA’s position as scientific support. Plaintiffs point to the World Health Organization’s IARC, which classified glyphosate as “probably carcinogenic to humans” in 2015.
That scientific disagreement is at the heart of every trial. And in 2026, it remains unresolved at the highest legal levels.
| Bayer Roundup Litigation Milestones |
|---|
| 2015: IARC classifies glyphosate as “probably carcinogenic” |
| 2018: Bayer acquires Monsanto for $63 billion |
| 2019: Johnson v. Monsanto verdict: $78.5 million to plaintiff |
| 2020: Bayer announces $10.9 billion settlement agreement |
| 2021 to 2023: Claims processing and payout distribution begins |
| 2024 to 2025: Supreme Court preemption petitions filed |
| 2026: Ongoing state trials, new claims in litigation |
The company’s stock price has been sensitive to each major court ruling, which tells you how seriously Bayer’s own investors take this litigation risk.
Key Takeaway: The Roundup lawsuit is not fully over in 2026. Bayer resolved most earlier claims, but new cases and the unresolved Supreme Court preemption question mean this litigation continues to affect thousands of people.
Roundup Lawsuit Settlement Timeline 2026
Think of the Roundup litigation like a river that forks into multiple streams. The original 2020 settlement was the main channel. But several smaller streams are still running.
Here is a chronological breakdown of where things stand:
| Year | Major Development |
|---|---|
| 2015 | IARC calls glyphosate “probably carcinogenic to humans” |
| 2018 | Bayer buys Monsanto; inherits all Roundup liability |
| August 2018 | Johnson v. Monsanto: jury awards $289 million (later reduced) |
| March 2019 | Hardeman v. Monsanto: federal jury finds Roundup caused plaintiff’s cancer |
| May 2019 | Pilliod v. Monsanto: couple awarded $2 billion (later reduced) |
| June 2020 | Bayer announces $10.9 billion settlement for roughly 125,000 claims |
| 2021 to 2023 | Individual claims evaluated; payments distributed to qualifying plaintiffs |
| 2024 | Bayer seeks Supreme Court review of preemption defense |
| 2025 | Additional individual trial verdicts; new claims continue filing |
| 2026 | Remaining cases in active litigation; preemption ruling still pending |
For plaintiffs in the 2020 settlement pool, most are either receiving payments or in final processing. For newer claimants, the timeline extends further out.
If you filed a claim after 2021, your case could realistically be in active litigation through 2027 or later.
Roundup Lawsuit Settlement Amounts
Roundup settlements are not one-size-fits-all. Payouts depend heavily on diagnosis, age, extent of harm, and how long the person used Roundup.
The 2020 settlement agreement did not establish fixed amounts publicly. Instead, it created a tiered evaluation process managed through a court-supervised claims administrator.
Based on reported outcomes and legal analysis:
| Claim Tier | Estimated Settlement Range |
|---|---|
| Serious cases (advanced cancer, long-term use) | $100,000 to $250,000+ |
| Moderate cases (diagnosed, treated, in remission) | $50,000 to $100,000 |
| Less severe cases (limited use, less documentation) | $5,000 to $50,000 |
| Cases with weak documentation | May be denied or minimal offer |
Individual trial verdicts, by contrast, have been dramatically higher. The original Johnson verdict was $289 million before reduction. The Pilliod verdict reached $2 billion before reduction. Trial verdicts go through post-trial motions and appeals, which typically reduce the final amount significantly.
For most individual claimants, the settlement process offers faster resolution than going to trial. Trials take years and carry risk.
Bold fact: Bayer has reportedly paid out between $8,000 and $160,000 to individual plaintiffs depending on case strength, according to legal reporting from various mass tort analysts.
Average Roundup Settlement Amount
The average Roundup settlement amount is difficult to pin down with precision because settlement agreements often include confidentiality terms.
However, legal observers and mass tort analysts have reported a general range. Based on available public data and reporting:
Average settlement for qualifying Roundup claims: approximately $40,000 to $70,000 per plaintiff.
That range shifts based on several factors:
- Cancer severity: More advanced diagnoses receive higher offers
- Duration of Roundup exposure: Longer use periods strengthen causation arguments
- Age at diagnosis: Younger plaintiffs with more life years affected often receive more
- Medical expenses: Documented treatment costs increase the settlement value
- Prior verdicts in similar cases: Jury award trends in your jurisdiction matter
It is worth being clear about one thing: “average” includes a wide spread. Some claimants received less than $10,000. Others received six-figure payouts. Your specific situation determines where you fall.
Comparing this to other mass torts gives perspective. Talcum powder cases with cancer diagnoses have averaged in similar ranges. The 3M earplug settlement paid between a few thousand dollars and tens of thousands per veteran. Roundup’s per-plaintiff average is on the higher end of major mass torts given the severity of non-Hodgkin’s lymphoma as a diagnosis.
Roundup Settlement Payout Per Person
What actually determines your individual payout is a point-based evaluation system used in the settlement process.
Claims administrators and attorneys evaluate each plaintiff’s case against a matrix of factors. The process is similar to how insurance companies calculate injury claims, but applied in a legal context.
Key factors that affect your per-person payout:
- Type of non-Hodgkin’s lymphoma diagnosed: Diffuse large B-cell lymphoma tends to score higher than some other subtypes
- Treatment history: Chemotherapy, radiation, bone marrow transplants increase documented harm
- Years of Roundup use: More years generally means stronger causation evidence
- How Roundup was used: Farming and landscaping professionals who used it regularly have stronger claims than occasional homeowners
- Documentation quality: Medical records, purchase receipts, doctor letters all increase claim value
| Factor | Impact on Payout |
|---|---|
| Diagnosed with aggressive lymphoma | High positive impact |
| 10+ years of regular Roundup use | High positive impact |
| Strong medical documentation | High positive impact |
| Professional applicator (farmer, landscaper) | Moderate positive impact |
| Diagnosed but cancer in remission | Moderate positive impact |
| Limited or recreational Roundup use | Lower impact, smaller payout |
| Minimal documentation | Significant negative impact |
One thing that surprises many claimants: the claims process is not automatic. You do not simply file a form and receive a check. Your case must be evaluated, and that evaluation takes time.
Key Takeaway: Roundup settlement payouts are not equal for everyone. Stronger diagnoses, longer exposure periods, and better documentation lead to significantly higher individual payouts, with top-tier cases reaching six figures.
Roundup Cancer Settlement Fund
The $10.9 billion Bayer committed in 2020 was not a single pot of money divided equally among plaintiffs.
It was structured as a resolution program with separate components. The bulk of the funds covered the roughly 95,000 claimants who had already filed as of the agreement. An additional portion was reserved for future claimants who had not yet filed but would qualify.
Bayer also proposed a $1.25 billion research and class settlement fund specifically to address future claimants who might be diagnosed after the original settlement. That portion was rejected by a federal appellate court in 2021 because it attempted to limit future plaintiffs’ rights without fully compensating them.
That rejection matters in 2026. It means future claimants, people diagnosed after the original settlement wave, still have the right to pursue individual litigation or future settlement programs.
The current status of the fund in 2026:
| Fund Component | Status |
|---|---|
| Original $10.9 billion (existing claims) | Substantially distributed |
| Future claimants fund ($1.25 billion) | Rejected by court, ongoing litigation |
| Ongoing reserves for new claims | Bayer has set aside additional funds |
| Individual trial verdicts | Separate from the settlement fund |
Bayer’s financial disclosures continue to reference Roundup litigation reserves, which signals the company knows this is not fully behind them yet.
Who Qualifies for Roundup Settlement
You may qualify for a Roundup settlement if you used Roundup regularly and were later diagnosed with a qualifying form of cancer.
The general eligibility criteria that apply to most Roundup claims:
- Used Roundup herbicide: Must have personal exposure, not just household proximity
- Diagnosed with non-Hodgkin’s lymphoma or a related blood cancer
- Diagnosis linked to Roundup use: Medical records must support causation
- Diagnosis occurred after a period of regular Roundup use
- Within the statute of limitations: Most states allow two to three years from diagnosis or discovery of the connection
People who have a stronger qualifying profile:
- Farmers, landscapers, groundskeepers who used Roundup professionally
- Homeowners who used Roundup regularly over many years
- People diagnosed within the last several years with no other clear risk factors
People who likely do not qualify:
- People who used Roundup once or a handful of times
- People without a cancer diagnosis
- People whose statute of limitations has expired
| Eligibility Factor | Qualifies | May Not Qualify |
|---|---|---|
| Cancer diagnosis | Non-Hodgkin’s lymphoma, B-cell lymphoma | No cancer diagnosis |
| Roundup exposure | Regular, long-term use | One-time or minimal use |
| Timing | Within statute of limitations | Expired time window |
| Documentation | Medical records available | No supporting records |
The statute of limitations is one of the most commonly missed issues. If you were diagnosed years ago and did not file, your window may be closing or already closed depending on your state.
What Cancers Qualify for the Roundup Lawsuit
Non-Hodgkin’s lymphoma is the primary qualifying cancer for Roundup lawsuits.
Non-Hodgkin’s lymphoma is not one disease. It is a category of blood cancers that affect the lymphatic system. Several subtypes fall under this umbrella, and most of them can qualify.
Qualifying cancer subtypes include:
- Diffuse large B-cell lymphoma (DLBCL), the most common type in Roundup cases
- Follicular lymphoma
- Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL)
- Mantle cell lymphoma
- Marginal zone lymphoma
- T-cell lymphoma (certain subtypes)
- Hairy cell leukemia
- Burkitt lymphoma
Cancers that generally do not qualify:
- Hodgkin’s lymphoma (a distinct disease from non-Hodgkin’s)
- Pancreatic cancer
- Lung cancer
- Prostate cancer
- Most solid tumor cancers not related to the lymphatic system
| Cancer Type | Qualifies for Roundup Lawsuit |
|---|---|
| Diffuse large B-cell lymphoma | Yes |
| Follicular lymphoma | Yes |
| CLL / SLL | Yes |
| Mantle cell lymphoma | Yes |
| Non-Hodgkin’s lymphoma (general) | Yes |
| Hodgkin’s lymphoma | No |
| Lung cancer | No |
| Breast cancer | No |
| Colon cancer | No |
The science behind this distinction matters. IARC’s 2015 review found a specific statistical association between glyphosate exposure and non-Hodgkin’s lymphoma, not cancer broadly. Plaintiffs’ attorneys use that research as a foundation.
Key Takeaway: Non-Hodgkin’s lymphoma is the core qualifying diagnosis for Roundup claims. Several subtypes qualify, but Hodgkin’s lymphoma and most solid tumor cancers fall outside the typical eligible category.
Roundup Lawsuit Eligibility Requirements
Meeting the basic cancer and exposure criteria is the starting point, but eligibility involves more than just a diagnosis.
Think of it like qualifying for a mortgage. Having income matters. But so does your credit history, your debt levels, and your documentation. One piece alone is not enough.
Full eligibility requires meeting several requirements together:
1. Confirmed cancer diagnosis:
You need medical records showing a formal diagnosis of non-Hodgkin’s lymphoma or a qualifying subtype. A family history alone does not qualify.
2. Documented Roundup exposure:
Ideally, you can show years of regular use. Receipts, photos, employment records, or witness statements help. Professional users have an easier time proving this than homeowners.
3. Plausible causation:
Your attorney and medical experts must be able to argue that Roundup exposure more likely than not contributed to your cancer. Cases with no other known risk factors are stronger.
4. Within the filing deadline:
Every state has a statute of limitations, typically two to three years from diagnosis or from when you reasonably should have known about the Roundup-cancer connection.
5. Not already settled:
If you received a prior settlement payment related to Roundup, you may have signed a release that prevents further claims.
| Requirement | What It Means for You |
|---|---|
| Cancer diagnosis | Non-Hodgkin’s lymphoma, confirmed by medical records |
| Roundup exposure | Regular use over months or years |
| Causation argument | Exposure preceded diagnosis; few other risk factors |
| Statute of limitations | Generally 2 to 3 years from diagnosis |
| No prior release | Not already settled or signed away rights |
Meeting all five gives you a strong claim. Missing one of them does not automatically disqualify you, but it does weaken the case significantly.
How to File a Roundup Lawsuit Claim
Filing a Roundup claim in 2026 starts with connecting with a mass tort attorney, not a claims website or a general personal injury lawyer.
Here is the general process:
Step 1: Initial consultation
An attorney reviews your diagnosis, exposure history, and documentation. Most mass tort firms handle Roundup cases on contingency, meaning you pay nothing upfront and the attorney takes a percentage only if you recover.
Step 2: Case evaluation
The firm gathers your medical records, employment history, and any documentation of Roundup use. They may consult with a medical expert to assess causation.
Step 3: Filing the complaint
Your attorney files a complaint in the appropriate court. Depending on your case, this could go into the federal MDL in the Northern District of California or into your state’s courts.
Step 4: Discovery
Both sides exchange evidence. This includes your medical records, Bayer’s internal documents, and expert reports. This phase takes months to years.
Step 5: Settlement negotiation or trial
Most cases settle before trial. If no settlement is reached, your case may go before a jury. Trial cases take longer but sometimes result in higher awards.
| Filing Stage | Estimated Timeframe |
|---|---|
| Initial consultation | Days to weeks |
| Case evaluation and filing | 1 to 3 months |
| Discovery phase | 6 to 18 months |
| Settlement negotiation | Ongoing throughout litigation |
| Trial (if no settlement) | 2 to 4+ years from filing |
The most important step is the first one. Getting your claim evaluated by an attorney now puts you ahead of potential deadline issues.
Roundup Lawsuit Filing Deadline 2026
The filing deadline for a Roundup claim depends on which state you live in and when you were diagnosed.
Every state has a statute of limitations for personal injury lawsuits. For Roundup cases, the clock typically starts running from:
- The date of your cancer diagnosis, OR
- The date you reasonably discovered the potential link between Roundup and your cancer
Most states allow two to three years from that trigger date.
| State | Statute of Limitations |
|---|---|
| California | 2 years from diagnosis or discovery |
| Texas | 2 years from diagnosis or discovery |
| Florida | 2 years from diagnosis or discovery |
| New York | 3 years from diagnosis or discovery |
| Illinois | 2 years from diagnosis or discovery |
| Pennsylvania | 2 years from diagnosis or discovery |
A few important points about the discovery rule: courts have debated when a Roundup user “should have known” about the cancer connection. The IARC 2015 report created widespread public awareness. Plaintiffs diagnosed before 2015 may face arguments that their clock started in 2015.
If you were diagnosed in 2022 or 2023 and live in a two-year state, your window may already be closing in 2024 or 2025. Do not wait.
The original federal MDL is not accepting new cases automatically. New claimants typically file individual cases that may eventually be coordinated with the MDL or heard separately.
Key Takeaway: Filing deadlines are real and unforgiving. If you were diagnosed with non-Hodgkin’s lymphoma and used Roundup regularly, the statute of limitations in your state may expire soon. The clock started running at diagnosis or discovery, not when you decided to look into it.
Roundup Glyphosate Cancer Link
The entire Roundup lawsuit rests on one scientific question: does glyphosate cause non-Hodgkin’s lymphoma?
The answer depends on which scientific authority you ask, and that split is exactly why this litigation has lasted so long.
IARC’s position (WHO): In 2015, the International Agency for Research on Cancer classified glyphosate as “Group 2A: probably carcinogenic to humans.” This classification was based on epidemiological studies and animal research showing a pattern of association with non-Hodgkin’s lymphoma.
EPA’s position: The U.S. Environmental Protection Agency has consistently concluded that glyphosate is “not likely to be carcinogenic to humans” when used as directed. The EPA reviews different evidence sets and applies different evaluation standards than IARC.
This is not a small disagreement. It is the central battlefield of the entire legal fight.
| Scientific Authority | Position on Glyphosate |
|---|---|
| IARC (WHO) | “Probably carcinogenic to humans” (Group 2A) |
| U.S. EPA | “Not likely to be carcinogenic to humans” |
| European Food Safety Authority | Generally not classified as carcinogenic |
| Independent epidemiological studies | Mixed results; many show elevated NHL risk |
Plaintiffs rely on IARC and independent studies. Bayer relies on EPA conclusions and its own research. Juries have sided with plaintiffs in multiple trials, awarding billions of dollars. That tells you something about how ordinary people weigh the evidence when they hear both sides.
Bayer Roundup MDL Case
MDL 2741 refers to the federal multidistrict litigation consolidating Roundup personal injury cases in the Northern District of California.
MDL stands for multidistrict litigation. It is not a class action. Think of it as a way for courts to manage hundreds of similar individual cases at once without running separate trials for each one. The science, the evidence, and the pretrial procedures are handled centrally. But each plaintiff’s case remains individual.
Key facts about MDL 2741:
- Filed in the U.S. District Court for the Northern District of California
- Presided over by Judge Vince Chhabria
- Bellwether trials included Johnson, Hardeman, and Pilliod cases
- Bellwether verdicts resulted in jury awards for plaintiffs in multiple instances
- The MDL produced significant discovery of Monsanto’s internal documents, revealing communications about the company’s awareness of potential risks
By 2026, the MDL has served its main purpose. The bellwether trials generated the pressure that led to the 2020 settlement. Most MDL cases have resolved or are resolving. New cases filed in 2024 and 2025 may enter or relate to the MDL, but the litigation center of gravity has shifted to individual state court actions and the preemption fight at the Supreme Court level.
| MDL 2741 Key Facts |
|---|
| Court: U.S. District Court, N.D. California |
| Judge: Vince Chhabria |
| Cases Consolidated: Thousands |
| Key Bellwether Verdicts: Johnson (2018), Hardeman (2019), Pilliod (2019) |
| Settlement: $10.9 billion announced June 2020 |
| Status in 2026: Mostly resolved; ongoing management of remaining cases |
Roundup Weed Killer Lawsuit Explained
The Roundup lawsuit is a mass tort action against Bayer (formerly Monsanto) alleging that Roundup herbicide causes cancer and that the company failed to warn users about that risk.
Roundup is the best-selling herbicide in the world. Its active ingredient is glyphosate. Farmers, landscapers, homeowners, and golf course workers have used it for decades. The product is sprayed on weeds to kill them.
The problem, according to plaintiffs, is that Monsanto knew about potential cancer risks and chose not to add a warning label. Internal company documents uncovered during litigation showed communications suggesting executives were aware of scientific concerns but took steps to influence research outcomes and regulatory decisions.
That failure-to-warn argument is the core of every Roundup lawsuit. It is not just “Roundup is dangerous.” It is “Monsanto knew, or should have known, and did not tell you.”
Why does this matter for you in 2026?
If you used Roundup and developed non-Hodgkin’s lymphoma, you may have a product liability claim based on:
- Negligence in product design or labeling
- Strict liability for selling a dangerous product without adequate warnings
- Fraudulent concealment of known risks
The litigation is not a class action. Each plaintiff has an individual case evaluated on its own facts. You are not splitting a single pot of money with thousands of others. Your payout, if any, is based on your specific diagnosis, exposure, and damages.
Frequently Asked Questions
When will the Roundup lawsuit be settled for all remaining cases?
A complete settlement of all remaining Roundup cases is not expected in 2026.
Bayer resolved most existing claims through its 2020 agreement, but new lawsuits are still being filed and litigated.
A final global resolution depends partly on how the Supreme Court rules on Bayer’s preemption defense, which remains pending.
How much money can I get from the Roundup settlement in 2026?
Most qualifying Roundup claimants have received between $40,000 and $70,000 on average, though amounts vary widely.
Serious cases involving advanced cancer and long-term professional exposure have reached $100,000 to $250,000 or more.
Cases with minimal documentation or short exposure periods typically receive lower offers.
What type of cancer qualifies for the Roundup lawsuit?
Non-Hodgkin’s lymphoma is the primary qualifying diagnosis for Roundup claims.
Specific subtypes include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia, among others.
Hodgkin’s lymphoma, lung cancer, and most solid tumor cancers generally do not qualify.
Can I still file a Roundup lawsuit claim in 2026?
Yes, new Roundup claims can still be filed in 2026 if you are within your state’s statute of limitations.
Most states allow two to three years from the date of diagnosis or from when you discovered the potential Roundup-cancer link.
Anyone diagnosed in 2023 or later who lives in a two-year state should act quickly to avoid missing the deadline.
What is the difference between the Roundup class action and the mass tort cases?
The Roundup litigation is a mass tort, not a traditional class action, which is an important distinction.
In a class action, all plaintiffs share a single settlement divided among the group; in a mass tort, each plaintiff has an individual case evaluated on their own specific facts and damages.
Your payout in a Roundup mass tort depends on your diagnosis, your exposure history, and your documentation, not on splitting a pot equally with thousands of others.
Where Things Stand and What to Do Next
The Roundup lawsuit is still active in 2026. For people already in the settlement process, payments are continuing. For people who have not yet filed, the window is narrowing but not closed in most states.
If you used Roundup regularly and were diagnosed with non-Hodgkin’s lymphoma, the most important step is getting your situation evaluated before a statute of limitations deadline cuts off your options.
The litigation will not wait. Bayer’s preemption push could change the entire landscape for future plaintiffs at any point.
